Humana: Medicare Advantage Is Just A Short-Term Problem
Portfolio Pulse from
Humana's stock has declined due to short-term issues with Medicare Advantage, but the long-term outlook remains positive. The company's CenterWell coordinated care is not yet factored into its strategy. A buy rating is maintained with a price target of $370, indicating a 28% upside.
December 05, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Humana's stock has declined 18% due to short-term Medicare Advantage issues, but the long-term outlook is positive. CenterWell care is not yet priced into the strategy. A buy rating is maintained with a $370 price target, suggesting a 28% upside.
The article highlights short-term challenges with Medicare Advantage affecting Humana's stock, but emphasizes the long-term potential and the unpriced CenterWell care. The maintained buy rating and price target suggest a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100